On the other hand, the clinical decision support system (NAVIFY Mutation Profiler) used in our clinical ctDNA test pipeline suggested potential sensitivity to treatment with a combined regimen of PI3K and MEK inhibitors in CRC patients with KRAS G12V mutation or with concurrent KRAS and APC mutations [22,23]. This evidence concerns the gene APC and colorectal carcinoma.